3/27
04:09 pm
dyn
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer [Yahoo! Finance]
Low
Report
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer [Yahoo! Finance]
3/27
04:05 pm
dyn
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
Low
Report
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
3/27
08:33 am
dyn
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium [Yahoo! Finance]
Medium
Report
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium [Yahoo! Finance]
3/27
08:30 am
dyn
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
Medium
Report
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
3/26
10:44 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $47.00 price target on the stock.
Medium
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $47.00 price target on the stock.
3/25
07:45 am
dyn
Dyne Therapeutics Announces CEO Transition [Yahoo! Finance]
Medium
Report
Dyne Therapeutics Announces CEO Transition [Yahoo! Finance]
3/25
07:30 am
dyn
Dyne Therapeutics Announces CEO Transition
Medium
Report
Dyne Therapeutics Announces CEO Transition
3/13
07:52 am
dyn
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days [Yahoo! Finance]
Low
Report
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days [Yahoo! Finance]
3/13
07:30 am
dyn
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
Low
Report
Dyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
3/8
05:08 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its price target raised by analysts at Chardan Capital from $20.00 to $31.00. They now have a "buy" rating on the stock.
Medium
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its price target raised by analysts at Chardan Capital from $20.00 to $31.00. They now have a "buy" rating on the stock.
3/7
01:39 pm
dyn
Dyne Therapeutics Inc (DYN) Reports Encouraging Clinical Data and Financial Growth for Q4 and ... [Yahoo! Finance]
Neutral
Report
Dyne Therapeutics Inc (DYN) Reports Encouraging Clinical Data and Financial Growth for Q4 and ... [Yahoo! Finance]
3/6
01:35 pm
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
3/6
10:31 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its price target raised by analysts at Stifel Nicolaus from $35.00 to $41.00. They now have a "buy" rating on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its price target raised by analysts at Stifel Nicolaus from $35.00 to $41.00. They now have a "buy" rating on the stock.
3/6
09:36 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its price target raised by analysts at Piper Sandler from $27.00 to $29.00. They now have an "overweight" rating on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its price target raised by analysts at Piper Sandler from $27.00 to $29.00. They now have an "overweight" rating on the stock.
3/5
03:22 pm
dyn
Dyne: H2 2024 Muscle Disease Data Could Boost Value [Seeking Alpha]
Low
Report
Dyne: H2 2024 Muscle Disease Data Could Boost Value [Seeking Alpha]
3/5
08:14 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $47.00 price target on the stock, up previously from $44.00.
High
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $47.00 price target on the stock, up previously from $44.00.
3/5
07:44 am
dyn
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights [Yahoo! Finance]
Medium
Report
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights [Yahoo! Finance]
3/5
07:30 am
dyn
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Medium
Report
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
3/2
12:10 am
dyn
CEO & President Joshua Brumm Sells 100,000 Shares of Dyne Therapeutics Inc (DYN) [Yahoo! Finance]
Medium
Report
CEO & President Joshua Brumm Sells 100,000 Shares of Dyne Therapeutics Inc (DYN) [Yahoo! Finance]
2/21
03:18 pm
dyn
Dyne Therapeutics: An Updated Analysis [Seeking Alpha]
Low
Report
Dyne Therapeutics: An Updated Analysis [Seeking Alpha]
2/20
07:17 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $36.00 price target on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $36.00 price target on the stock.
2/20
07:17 am
dyn
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $36.00 price target on the stock.
Low
Report
Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $36.00 price target on the stock.
2/14
04:15 pm
dyn
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
Low
Report
Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
2/1
07:37 am
dyn
Dyne Therapeutics to Present at February Investor Conferences [Yahoo! Finance]
Low
Report
Dyne Therapeutics to Present at February Investor Conferences [Yahoo! Finance]
2/1
07:30 am
dyn
Dyne Therapeutics to Present at February Investor Conferences
Medium
Report
Dyne Therapeutics to Present at February Investor Conferences